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Background: The management of liver metastases from nasopharyngeal carcinoma (NPC) has not been extensively
investigated. This study aimed to compare the long-term outcome of patients with liver metastases from NPC who
were treated by a partial hepatectomy or transcatheter hepatic artery chemoembolization (TACE).
Methods: Between January 1993 and December 2010, 830 patients were diagnosed with liver metastases from NPC
and exhibited a complete response to the primary cancer of the nasopharynx and regional lymph nodes. Fifteen
patients with intrahepatic metastasis underwent R0 partial hepatectomy. As a parallel control group, another 15
patients with a resectable liver metastasis who underwent TACE were selected. Prior to the resection and TACE that
were performed on patients in these two groups, radical radiotherapy with or without adjuvant chemotherapy was
administered. Clinicopathological data and treatment outcomes were compared retrospectively.
Results: No significant differences were observed between the two groups in terms of the clinicopathological
features, which include gender ratio, liver function, accompanying cirrhosis, rate of infection with the hepatitis B
virus, tumor size, tumor number, pathological type and preoperative comorbidities. The 1-, 3- and 5-year overall
survival rates from the time of hepatectomy were 85.7%, 64.2% and 40.2%, respectively, with a median survival of
45.2 months, whereas the 1-, 3- and 5-year overall survival rates were 53.3%, 26.6% and 20.0% for patients in the
control group (P = 0.039), respectively, with a median survival of 14.1 months. The actuarial median progression-free
survival (PFS) of the patients in the resection group was 21.2 months, and the 1-, 3- and 5-year PFS rates were 70%,
53% and 18%, respectively. In the control group, the 1-, 3- and 5-year PFS rates were 27%, 7% and 0.0% (P = 0.007),
respectively, with a median survival of 4.2 months. Thus far, 5 patients have survived for more than 5 years, and the
longest survival time is 168.1 months.
Conclusions: For patients with limited liver metastases from NPC, hepatectomy provides a survival advantage over
TACE. Due to the limited treatment options for patients with liver metastasis from NPC, hepatectomy should be
recommended as an optimal treatment. Moreover, perioperative chemotherapy may be associated with an
improved prognosis.
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Nasopharyngeal carcinoma (NPC) is a common disease
among Asians, especially the Southern Chinese. The in-
cidence of the disease is 20–30 per 100,000 in Southeast
Asia and less than 1 per 100,000 in western countries
[1]. In contrast to other squamous cell carcinomas of
the head and neck, NPC is characterized by a high ten-
dency for metastatic dissemination [2]. The most common
pathological type of NPC is non-keratinizing undifferenti-
ated carcinoma (95% of patients in Southern China and
63% in North America), which can be managed with
proper treatment, but has a high incidence of distant
metastasis, compared to the other two types of NPC,
squamous cell carcinoma and keratinizing undifferentiated
carcinoma [1,3]. NPC has a tendency to develop distant
metastasis to the following organs: bones, lungs, liver, and
distant lymph nodes, which is the main cause of death
of patients with NPC [4]. The liver is one of the most
common site of metastases from NPC; liver metastasis
is usually multifocal with a worse prognosis than metasta-
sis to the lung or bone [5]. Many patients with NPC who
have liver metastasis are not eligible for a hepatectomy be-
cause of multiple lesions or the presence of extra-hepatic
metastases. Although a high objective response rate has
been obtained in some cases of metastatic NPC using
chemoembolization and chemotherapy, these treatments
are palliative and the patients’ overall survival rates are
still not satisfactory [6-8].
The role of partial hepatectomy for hepatic metastasis
from NPC is not well- documented. Hepatectomy for
solitary colorectal liver metastasis is well-recognized as a
standard treatment [9,10]. However, very few studies
have reported on the curative effect of hepatic resection
for liver metastases from NPC. To our knowledge, the
present study provides the largest consecutive series of
patients treated by hepatectomy for liver metastases
from NPC. This study aimed to identify the long-term
outcome in patients with liver metastases from NPC
who underwent hepatectomy and to compare the results
with those who underwent TACE.
Methods
Patients
This retrospective study was approved by the ethics
committee of Sun Yat-Sen University Cancer Center, and
was in accordance with the Helsinki Declaration of 1975,
as revised in 1983. Between January 1993 and December
2010, 830 consecutive patients with newly diagnosed liver
metastases from NPC were treated in the Sun Yat-Sen
University Cancer Center. NPC was histologically con-
firmed in all patients. The diagnosis of liver metastasis
was based on histological evaluation, ultrasound and com-
puted tomography of the abdomen. Patients with other
malignant tumors were excluded. Among the 830 patients,86 patients without extrahepatic metastases from NPC
underwent partial hepatectomy or TACE. Of these
cases, 15 patients who underwent partial hepatectomy
were enrolled in the resection group. Of the 71 patients
who underwent TACE, 15 patients with resectable hepatic
metastatic lesions were treated with TACE because the pa-
tients refused to accept operation. These 15 patients were
selected as the control group. Each group was composed
of 12 males and 3 females, with a median age of 46 and
43 years in the resection group and the TACE group,
respectively.
Procedures
Computed tomography (CT) scans or magnetic resonance
imaging (MRI) of the head and neck showed a complete
response of all the primary carcinomas after radical radio-
therapy with or without adjuvant chemotherapy. Emission
computed tomography (ECT) for bones and CT for chest,
or positron emission tomography-computed tomography
(PET-CT) was performed to rule out extra-hepatic
metastasis. Partial hepatectomy was performed only if
no evidence of local recurrence or extrahepatic distant
metastasis was observed, although there was no definite
indication for such surgical treatment; nevertheless, rare
cases were reported [11,12]. Cardiopulmonary function
and liver function, as determined by biochemical assays
and Child–Pugh grading, of each patient were estimated.
The criteria for resection were defined as follows: (1)
complete response of primary disease to therapy, (2) no
extrahepatic metastasis, and (3) solitary or multiple (no
more than 5) liver metastases with at least two lesion-free
segments. Partial hepatectomy was defined as the removal
of the tumor plus a rim of non-neoplastic liver paren-
chyma, without regard to the anatomic segments as
described by the Couinaud classification [13]. Major
hepatectomy was defined as the resection of three or
more hepatic segments according to Couinaud’s classifica-
tion, and minor hepatectomy was defined as a resection of
fewer than three hepatic segments [14,15]. R0 resection
was defined as a resection with a microscopically negative
margin. An indocyanine green retention rate of 15 min
(ICGR15) [16] was used to evaluate the liver function
reserve. Intraoperative ultrasonography was also routinely
used.
We used our previously reported protocol [17] for
TACE, which was performed by the administration of
50 mg of epidoxorubicin, 300 mg of paraplatin and
6 mg of mitomycin, mixed 1:1 in an emulsion with lipio-
dol. The amount of lipiodol varied and was dependent
on the tumor burden and vascular supply.
The treatments for tumor recurrence after hepatectomy
included combinations of chemotherapy, radiofrequency ab-
lation (RFA), percutaneous microwave ablation (PMA), and
percutaneous ethanol injection (PEI). Hospital mortality
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and all deaths that occurred during the same hospital
admission.
The baseline data, including gender, age, hepatitis B
virus infection, test for Epstein-Barr (EB)-related virus
infection, liver function, synchronous or metachronous
presentation of liver metastases with primary tumor, and
comorbidities before hepatectomy, were collected and
analyzed. In addition, the clinicopathological data and
treatment results including radical or palliative resection,
operative procedure, tumor burdens, postoperative com-
plications, the interval from treatment to recurrence or
metastasis, and the survival rates after treatment were
considered. Overall survival (OS) was reported from
the date of hepatectomy or TACE, while progression-
free survival (PFS) was defined as the interval from
the date of hepatectomy or TACE to the progression
of the tumor, whether it was a local or a distant recur-
rence. Patients with any evidence of macroscopic le-
sions after hepatic resection were excluded from PFS
analysis.
Follow-up
The duration of follow-up was calculated from the day
of hepatectomy or TACE to either the date of death or
the last follow-up visit. The study was censored on May
30th, 2013. Follow-up imaging (contrast-enhanced CT
or MRI) was performed after treatment. Further treat-
ments were based on clinical evaluation, laboratory
values, and imaging response. Patients with stable
disease were imaged every 3–4 months. The follow-up
visits consisted of a physical examination, routine blood
tests, liver function tests, a determination of serum
VCA-IgA and EA-IgA levels, an abdominal ultrasonog-
raphy or computed tomography scan, a chest X-ray, and
head and neck MRI. A bone scan or a positron emission
tomography–computed tomography (PET-CT) scan was
performed when there was evidence of local recurrence
or distant metastasis.
Statistics
The statistically significant differences in categorical
and continuous numerical variables between the pa-
tients in the resection group and those in the control
group were calculated using the Pearson chi-square test
with Fisher’s exact test and the unpaired Student’s t-test,
respectively. Overall survival rates and progression-free
survival rates were analyzed by the Kaplan–Meier
method, and the differences between the two groups
were compared by the log-rank test. Alpha was set at
0.05, and all tests were two-tailed. All statistical analyses
in this study were performed with the software package
SPSS (Statistical Package for the Social Sciences) 17.0
(SPSS Inc., Chicago, IL).Results
The characteristics of the 30 patients are summarized in
Table 1. The two groups were similar for all matching
criteria, and no significant differences were found between
the two groups with regards to demographics, tumor
characteristics, primary treatments, preoperational comor-
bidities and postoperative complications. The median age
was 46 years (range: 36–63 years) and 43 years (range:
26–63 years) for patients in the resection group and pa-
tients in the control group, respectively. Patients in the
resection group had the same proportion of men and
women as that of the control group, which was 12 men
and 3 women (P > 0.999). There were no significant dif-
ferences between the patients in the resection group
and patients in the control group in terms of laboratory
analyses, such as liver function and EB virus infection
rates. Although we found 3 cases with hepatitis B virus
infection, none of the patients suffered from severe
cirrhosis. At the time of admission, the liver function
grade for all patients was “A” according to the Child-Pugh
grading system. The diagnoses were confirmed histolog-
ically for patients in the resection group. For patients in
the control group, the 7 cases of metastases were con-
firmed histologically by a biopsy under the guidance of
CT or ultrasound. The remaining 8 cases were clinically
diagnosed by CT or magnetic resonance imaging with
evidence of progressive enlargement of a hepatic lesion.
The pathology type of all specimens was confirmed as
undifferentiated non-keratinizing carcinoma. Only 1 pa-
tient in the control group demonstrated a synchronous
NPC and liver metastasis, while the other 29 patients
were found to have metachronous development of liver
metastasis without any local recurrence. The number of
liver lesions was less than 3 with diameter of 1.5 to
10 cm in 24 patients (24/30, 80%) and 3 to 4, with diameter
of 1.5 to 7.0 cm in remaining 6 patients (6/30, 20%). Bone
scans, PET-CT scans and chest X-rays or CT imaging
showed no signs of bone, lung or other extrahepatic distant
metastases.
The treatments for the primary tumors in the two
groups included radiotherapy and adjuvant chemotherapy.
The median dose of radiation to treat the nasopharyngeal
carcinomas was 70 Gray (range: 68 to 76 Gy) and 70 Gy
(range: 66 to 78 Gy) in the resection group and the control
group, respectively. For the regional lymph nodes, the
median radiation dose was 66 Gy (range: 50 to 68 Gy)
and 64 Gy (range: 50 to 70Gy) in the resection group
and control group, respectively. No significant differ-
ences were found between the two groups (Table 2).
The primary chemotherapy regimen used was fluoro-
uracil (5-FU) combined with cisplatin (DDP) or other
protocols based on these two agents. Additionally, there
were no significant differences in the responses to adju-
vant chemotherapies between the two groups (Table 2).
Table 1 Clinicopathological factors in 30 patients with liver metastases from Nasopharyngeal Carcinoma
Resection group Control group P value
(n = 15) (n = 15)
Age (y) 46 (36–63) 43 (26–63) >0.999
Gender >0.999
Male 12 (80%) 12 (80%)
Female 3 (20%) 3 (20%)
Presentation >0.999
Synchronous 0 (0%) 1 (6.7%)
Metachronous 15 (100%) 14 (93.3%)
Abdominal symptom 0.598
Positive 1 (6.7%) 3 (20%)
Negative 14 (93.3%) 12 (80%)
Interval from NPC to hepatic metastasis 0.427
<12 (mo) 3 (20%) 6 (40%)
≥12 (mo) 12 (80%) 9 (60%)
PFS (mo) >0.999
<12 (mo) 7 (46.7%) 8 (53.3%)
≥12 (mo) 8 (53.3%) 7 (46.7%)
EBERs >0.999
Positive 15 (100%) 15 (100%)
Negative 0 (0%) 0 (0%)
Child-Pugh Grading >0.999
Grade A 15 (100%) 15 (100%)
Grade B 0 (0%) 0 (0%)
Hepatitis virus B infection >0.999
Positive 2 (13.3%) 1 (6.7%)
Negative 13 (86.7%) 14 (93.3%)
Continuous data were expressed as median (range).
Categorical variables were reported with (%).
PFS: progression-free survival from diagnosis of NPC to discovery of liver metastasis.3.
EBERs: Epstein-Barr -Virus encoded small RNAs.
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concurrent chemoradiotherapy for the primary tumor. All
of the patients showed a complete response of the regional
lymph nodes and nasopharyngeal mass after radiation
therapy and chemotherapy.
The interval from the diagnosis of the primary disease
to the identification of liver metastasis was similar be-
tween the two groups, with a median of 15.6 months for
patients in the resection group (range: 1.8 to 74.5 months)
versus 14.1 months for patients in the control group
(range: 0.0 to 37.5 months). Moreover, there was no
significant difference between the two groups in the
PFS from the complete response of primary tumors to
the occurrence of hepatic metastases. The median PFS was
12.6 months for patients in the resection group (range: 0.0
to 73.5 months) versus 11.9 months for patients in the
control group (range: 0.0 to 34.0 months).Of the 15 patients who underwent hepatic resection, no
obvious hepatitis or ascites was found prior to surgery.
Three patients underwent a major resection, and the
others underwent a minor resection, including segmen-
tal resection and local resection. After specimen dissec-
tion, 26 lesions were found in patients in the resection
group. Most of the metastatic masses were stiff with a
clear border, except for 2 lesions with an obscure border.
No capsule was found in the metastatic tumors. The
median surgical margin was 2.0 cm (range: 0.3 to 4.0 cm).
Each tumor specimen was carefully examined after
removal from the patient, and we found that most of the
hepatic NPC metastases displayed an infiltrating growth
pattern with a deficiency of blood supply and lack of a
capsule. Most of the lesions were isolated, and only two
tumors demonstrated invasion of the adjacent organs and
a thrombus.
Table 2 Liver metastases-related characteristics in 30 patients with liver metastases from Nasopharyngeal Carcinoma
Resection group Control group P value
(n = 15) (n = 15)
Lesion numbers >0.999
<3 12 (80%) 11 (73.3%)
≥3 3 (20%) 4 (26.7%)
Size of largest metastasis (cm) 0.450
<5 8 (53.3%) 11 (73.3%)
≥5 7 (46.7%) 4 (26.7%)
Pathological type >0.999
Undifferentiated 15 (100%) 15 (100%)
Other types 0 (0%) 0 (0%)
Dose of Primary Radiotherapy (Gy) >0.999
Nasopharyngeal 70 (68–76) 70 (66–78)
Regional lymph nodes 66 (50–68) 64 (50–70)
Adjuvant chemotherapy cycles of NPC 0.390
<3 10 (66.7%) 13 (86.7%)
≥3 5 (33.3%) 2 (13.3%)
Pre-resection/TACE comorbidities
Present 3 (20%) 4 (26.7%) >0.999
Absent 12 (80%) 11 (73.3%)
Post-resection/TACE comorbidities 0.651
Present 2 (13.3%) 4 (26.7%)
Absent 13 (86.7%) 11 (73.3%)
Hospital mortality 0 (0%) 0 (0%) >0.999
Continuous data were expressed as median (range).
Categorical variables were reported with (%).
NPC: nasopharyngeal carcinoma.
TACE: trans-hepatic arterial chemoembolization.
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of the hepatic NPC metastases in the TACE imaging. In
the control group, 13 patients had tumors that were
deficient in blood supply, and only 2 patients had tumors
with a rich blood supply. As universally accepted in TACE,
a deficient blood supply might weaken the effect of
chemotherapy or embolization because chemotherapeutic
agents depend on the blood supply to enter the tumor.
No perioperative deaths occurred in either group.
Compared to patients in the control group, patients in
the resection group showed no significant difference in
the incidence of preoperative comorbidities (P = 1.000).
One patient in the resection group exhibited postoperative
hepatic insufficiency, while another developed hydro-
thorax. Post-TACE complications were found in 4 patients
(26.7%, 4/15) in the control group.
The progression rate of the patients in the resection
group was 73.3% (11/15), which was lower than that of
the patients in the control group (100%, 15/15), but the
difference was not statistically significant (P = 0.330). In the
resection group, 7 patients developed only extra-hepaticmetastases, and 1 patients developed only intra-hepatic re-
currence and 3 patients had both intra- and extra-hepatic
metastatic lesions after resection. This is in contrast to the
control group, where 13 patients exhibited only intra-
hepatic progression, and 2 patients had both intra- and
extra-hepatic metastatic lesions. Multimodality therapies,
including systemic chemotherapy, repeated resection, re-
peated TACE, PEI, PWA, RFA, radiotherapy, and biother-
apy were used in the patients with progression. The types
of post-resection/TACE treatments for the two groups
were not significantly different (Table 3).
A total of 11 patients in the resection group demon-
strated a progression of the disease after partial hepatec-
tomy, while 2 of the 4 patients without progression
survived 168.1 and 13.0 months, respectively; the other
2 patients were censored because of lost follow-up.
However, in the control group, 15 patients had tumor
progression after TACE with one lost follow-up. The
median OS time after hepatectomy was 45.2 months
(range: 0.6 to 168.1 months), and the median OS time
of the control group was 14.1 months (range: 2.1 to
Table 3 Treatments after progression for 30 patients underwent resection or transarterial chemoembolization for liver
metastases from Nasopharyngeal Carcinoma
Resection group (n = 15) Control group (n = 15) P value
n % n %
All treatments after hepatectomy/TACE 13 12 >0.999
Systemic Chemotherapy 9 7 0.715
Radiation (NP recurrence) 1 2 >0.999
Repeat resection 1 0 >0.999
Repeat transarterial chemoembolization 2 8 0.021
Radiofrequency therapy 2 3 >0.999
Percutaneous ethanol injection treatment 1 0 >0.999
Percutaneous microwave ablation therapy 1 1 >0.999
Biological therapy 1 0 >0.999
Hepatic arterial infusion 1 2 >0.999
Observation 2 3 >0.999
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vived more than 5 years, including one 10-year survivor.
The median PFS of the two groups was 21.2 months
for patients in the resection group (range: 0.6 to
168.1 months) and 4.16 months for patients in the control
group (range: 0.7 to 38.1 months). The OS rates for 1, 3,
and 5 years after resection were 85.7%, 64.1%, and 40.2%
for patients in the resection group, and 53.3%, 26.6%, and
20.0% for patients in the control group (Table 4). The
postoperative long-term OS of the patients in the resec-
tion group was significantly better than that of patients in
the control group (P = 0.039; Figure 1). When stratified by
different resection methods, 11 patients underwent major
resections with a median OS of 56.0 ± 13.2 months, and 4
patients with minor resections only had a median OS of
10.7 ± 3.7 months (P = 0.036). The PFS at 1, 3, and 5 years
was 70.0%, 53.0%, and 18.0% for patients in the resectionTable 4 Long-term outcomes of the 30 patients with liver me
Resection grou
Median overall survival (mo) 45.2 ± 12.1
1-y overall survival (%) 85.7
3-y overall survival (%) 64.1
5-y overall survival (%) 40.2
Median progression-free survival (mo) 21.2 ± 11.0
1-y progression-free survival (%) 70.0
3-y progression-free survival (%) 53.0
5-y progression-free survival (%) 18.0
Progression (case) 11 (73.3%)
Intra-hepatic 1 (6.7%)
Extra-hepatic 7 (46.7%)
Both intra- and extra-hepatic 3 (20.0%)group and 27.0%, 7.0%, and 0.0% for patients in the
control group (P = 0.007; Figure 2). The postoperative
progression-free survival of patients in the resection
group was significantly better than that of patients in
the control group (P = 0.007; Figure 2).
Discussion
The main purpose of this study was to compare the out-
comes of patients with NPC and liver metastasis who were
treated with two different methods: partial hepatectomy
and TACE. Our study showed that partial hepatectomy
provided a survival advantage over TACE in patients with
NPC and liver metastasis.
It has been reported that 30% to 60% of patients with
locally advanced NPC will develop distant metastasis
within 5 years, of which 5% to 8% present distant metas-
tases at the time of diagnosis [2,18]. The most commontastases from Nasopharyngeal Carcinoma
p Control group P Value












Figure 1 The Kaplan–Meier survival analysis of the overall survival of the 15 patients with hepatic metastases from NPC who
underwent resection and the 15 patients who underwent transhepatic arterial chemoembolization.
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distant lymph nodes. 78.3% patients occurred bone me-
tastasis within 2 years after diagnosis of NPC, the overall
survival time after bone metastasis is 6–24 months with
a median of 12 months and the median survival time for
patients who accepted alleviative treatment is merely
4 months [19]. Lung is the second common site of metas-
tasis of NPC, patients with lung metastasis alone had a
median overall survival of 3.9 years, which is significantlyFigure 2 The Kaplan–Meier survival analysis of the progression-free s
underwent resection and the 15 patients who underwent transhepatilonger than that of other metastasis sites [20,21]. Although
liver has been reported to be the third most frequent site
of NPC metastasis, with an incidence of 29.3% to 36%
[22,23], liver metastasis was the worst factor against prog-
nosis: the median overall survival time after diagnosis of
liver metastasis was only 3-5months [24]. Combination
chemotherapy, which is usually palliative, is considered to
be the standard treatment for metastatic NPC, especially
for those patients with multiple metastases. The mosturvival of the 15 patients with hepatic metastases from NPC who
c arterial chemoembolization.
Huang et al. BMC Cancer 2014, 14:818 Page 8 of 10
http://www.biomedcentral.com/1471-2407/14/818common combination of cisplatin and 5-Fu was reported
to generate a 66-76% response rate [25]. In the past
20 years, a number of patients with only intrahepatic
metastases from NPC were experimentally treated with
TACE as local chemotherapy combined with systemic
chemotherapy. Despite the consensus regarding the
chemosensitivity of NPC, there were only a few, spor-
adic reports that concerned the surgical treatment of pa-
tients with NPC and hepatic metastases after a complete
response of the primary disease.
Due to recent advances in superior imaging techniques,
more accurate preoperative exams, and improvements in
the technical procedure of hepatectomy, hepatic resection
of liver metastases has led to more curative results with
fewer complications and lower mortality than in previous
years [26,27]. Hepatic resection has been reported to be
an effective and potentially curative treatment for patients
with liver metastases from colorectal and neuroendocrine
carcinoma with a 5-year survival rate of 16%-76%, de-
pending on the patients selected [28-30]. Compared to
these cases, partial hepatectomy for NPC and hepatic me-
tastases also provides a promising and inspiring outcome
[12,31]. In this study, to achieve satisfactory long-term
outcomes, patients with hepatic metastases in both groups
were strictly selected to avoid additional treatments for
aggressive tumors with multiple metastatic sites. Patients
who showed progression of extra-hepatic metastases after
the diagnosis of liver metastases were not referred to hep-
atectomy. In addition, the patients in the control group
were also well-matched to each patient in the resection
group. The patients’ baseline characteristics were statisti-
cally identical in the two groups to avoid bias.
When the patients were stratified according to the
method of hepatectomy, different survival results were
obtained. In our study, compared to patients with a
minor resection, the OS of the patients who underwent
major resections was significantly better (P = 0.036).
The comparison of outcomes between major and minor
resection suggest a wider surgical margin for tumor
resection may lead to better survival for the patients,
which is supported by studies on liver metastases fromTable 5 Review of previously reports of long term survival of
First author Year Case number OS (mo) PFS (mo) Metastasis s
Choo [37] 1991 1 36 36 Liver, bone
Chung [38] 1997 1 126 42 Liver, lung, b
Fandi [6] 2000 2 >93 >93 Liver
Ong [5] 2003 2 >60 NR Liver
Weitz [12] 2005 2 NR NR Liver
Delis [31] 2006 1 6 6 Liver
Khanfir [39] 2007 1 ≥36 NR Liver
NR: not reported.colorectal cancer [26]. However, a major resection de-
notes less remnant liver, which is also the main paradox
for hepatectomies for hepatocellular carcinoma (HCC).
Unlike patients with HCC, patients with hepatic NPC
metastases rarely have HBV infections, which lead to
cirrhosis and a propensity for insufficient liver function
after hepatectomy. Such characteristics of patients with
metastatic NPC may allow for a greater resection of par-
enchyma. In our study, although 2 patients in the resec-
tion group developed postoperative hepatic insufficiency,
both of them recovered within two weeks of hepatectomy;
no post-treatment mortality was found in this study. How-
ever, more cases should be enrolled in our future study to
further confirm the conclusion due to the limitated cases
in this study.
TACE is regarded as a minimally invasive treatment
protocol for liver metastasis [32]. It is also widely
accepted as the appropriate treatment for advanced stage
HCC [33] due to its limited damage to the liver and
other organs that cause postoperative complications. In
this study, patients in the resection group experienced
more complications than patients in the control group
(TACE), such as pain, fever, and severe hepatic insuffi-
ciency. However, after hepatectomy, none of the patients
died of complications, or from sequelae after their dis-
charge from the hospital. The treatments for progression
of disease after hepatectomy or TACE were not signifi-
cantly different between the two groups. We found 11
patients (73.3%, 11/15) in the resection group who expe-
rienced tumor recurrence after hepatectomy (37.0% at
1 year and 73.3% at 5 years) (Table 3). A total of 7 patients
in the resection group developed only extra-hepatic metas-
tases, and 1 patient developed only intra-hepatic recur-
rences and and 3 patients had both intra- and extra-hepatic
metastatic lesions after resection. However, in the con-
trol group, 13 patients had only intra-hepatic progres-
sion, and 2 patients had both intra- and extra-hepatic
metastases. The patients in the resection group had a
lower progression rate than patients in the control
group, although the difference was not statistically sig-
nificant (P = 0.330).liver metastasis from Nasopharyngeal Carcinoma
ites Treatments for liver metastasis from Nasopharyngeal Carcinoma
Cisplatin-based chemotherapy
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patients with metastatic NPC ranged from 20 to 52%
[2,6,18,34]. However, in our study, the OS rates after
hepatectomy at 1, 3, and 5 years were 85.7%, 64.1%, and
40.2%, respectively, for patients in the resection group.
For the control group, the results were similar to previ-
ously reported values, and the OS rates at 1, 3, and 5 years
were 53.3%, 26.6%, and 20.0%, respectively (Table 4). The
postoperative long-term survival of the patients in the
resection group was significantly better than that of the
patients in the control group (P = 0.039; Figure 1) and
that of patients from previous reports [2,6]. Moreover,
the patients in the resection group in our series had
statistically better PFS rates than patients in the control
group (P = 0.007; Figure 2). For primary or secondary
carcinoma of the liver, hepatectomy is regarded as a
curative treatment while TACE is regarded as a palliative
treatment. The radical removal of the tumor decreases the
chance for recurrence, while TACE leads to necrosis of
the tumor by local chemotherapy and embolization. An-
other explanation for the poor PFS of TACE compared to
hepatectomy is that TACE is based on a plentiful hepatic
arterial blood supply, and thus the effects on the tumors
were mostly dependent on this blood supply to the tumor.
However, in our study, pre-procedure-enhanced CT or
MRI and radiography of TACE showed that 13 of 15 pa-
tients had a poor blood supply to metastatic liver tumors,
while only 2 patients had a rich blood supply. The poor
blood supply impaired the expected effects on the tumor.
In our study, the patient mortality was primarily cancer-
related, and therefore the better PFS led to better OS for
patients in the resection group than for patients in the
control group. Furthermore, the disease-free interval
between treatment of the primary tumor and the devel-
opment of liver metastases is regarded as a surrogate
marker of tumor biology. A longer PFS may indicate a
less aggressive tumor; Teo and Ong reported that poor
PFS (≤6 months) was a negative prognostic factor in
metastatic NPC [35,36].
So far, in this study, there were 7 patients in the resection
group and 3 in the control group who survived more than
3 years after the end of the treatment. Among the 10
long-term survivors, 5 of the patients survived more than
5 years. The longest survivor has an overall survival time
of 168.1 months without recurrence. Based on these
results, we consider that patients in the resection group
benefitted from hepatic resection. However, because the
number of cases enrolled in our study was limited, we
could not perform a multivariate analysis using the Cox
proportional hazards model. Further research should be
conducted to identify the prognostic factors of hepatec-
tomy with a larger sample size.
The previously published long-term survival rates of
patients with liver metastasis of NPC were also reviewed(Table 5). To our knowledge, this is the largest series of
patients who were treated with resection for liver metas-
tases from NPC. Among all 7 studies, we found 10 pa-
tients with hepatic metastases of NPC who were treated
with chemotherapy. The longest overall survival time
was 126 months, and the longest disease-free survival
time was over 93 months. Only 3 patients had been
treated by resection. The role of liver resection was con-
troversial for patients with hepatic metastases due to a
few studies with limited numbers.
Conclusion
For the patients with resectable hepatic metastatic lesions,
partial hepatectomy should be recommended after
complete response of the primary tumor in the absence
of extra-hepatic dissemination. In patients with resectable
liver metastases from NPC, hepatic resection is safe and
could be offered to acquire better long-term survival.
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